Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression - BioSpace

Submitted by Anonymous (not verified) on Thu, 09/12/2019 - 13:26

Navitor's Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression  BioSpaceCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Navitor Pharmaceuticals, Inc., the leader in the discovery and development of mTORC1-targeted therapeutics ...